DaVita (DVA) to Announce Quarterly Earnings on Tuesday

DaVita (NYSE:DVA) is anticipated to release its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect DaVita to announce earnings of $3.88 per share and revenue of $3.4963 billion for the quarter. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. DaVita’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.00 earnings per share. On average, analysts expect DaVita to post $15 EPS for the current fiscal year and $18 EPS for the next fiscal year.

DaVita Stock Up 0.5%

NYSE:DVA opened at $240.00 on Friday. The company has a market cap of $15.41 billion, a P/E ratio of 22.26, a P/E/G ratio of 0.79 and a beta of 0.88. The firm’s 50 day moving average is $217.76 and its two-hundred day moving average is $173.13. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $244.49.

Insider Buying and Selling at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DaVita

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitlin John LLC acquired a new stake in DaVita in the fourth quarter valued at approximately $34,000. Canada Pension Plan Investment Board acquired a new position in shares of DaVita during the second quarter worth $43,000. Kestra Advisory Services LLC purchased a new position in shares of DaVita in the fourth quarter valued at $45,000. iSAM Funds UK Ltd acquired a new stake in DaVita during the 3rd quarter valued at $46,000. Finally, AlphaCentric Advisors LLC acquired a new stake in DaVita during the 4th quarter valued at $50,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DVA. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Truist Financial lifted their target price on DaVita from $205.00 to $250.00 and gave the company a “hold” rating in a report on Tuesday, July 14th. Barclays upped their price target on DaVita from $194.00 to $218.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 8th. TD Cowen raised their price objective on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a report on Monday, May 11th. Finally, Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and lifted their price objective for the company from $126.00 to $220.00 in a research note on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, DaVita has a consensus rating of “Hold” and an average target price of $216.50.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.